Daniel Betticher

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok, Yi‐Long Wu, Iveta Kudaba et al. · The Lancet · 2019 · 3.3K citations · Full text

Medicine, Oncology, Pharmacology +15

Mediastinal Lymph Node Clearance After Docetaxel-Cisplatin Neoadjuvant Chemotherapy Is Prognostic of Survival in Patients With Stage IIIA pN2 Non–Small-Cell Lung Cancer: A Multicenter Phase II Trial

Daniel Betticher, Shu‐Fang Hsu Schmitz, Martin Tötsch et al. · Journal of Clinical Oncology · 2003 · 455 citations

Medicine, Oncology, Pharmacology +17

Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial

Miklos Pless, Roger Stupp, Hans-Beat Ris et al. · The Lancet · 2015 · 390 citations

Medicine, Oncology, Radiation Oncology +13

SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non–Small-Cell Lung Cancer—A Multicenter Single-Arm Phase II Trial

Sacha I. Rothschild, Alfred Zippelius, E.I. Eboulet et al. · Journal of Clinical Oncology · 2021 · 341 citations

Medicine, Oncology, Pharmacotherapy +13

Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma

Walter Weder, Rolf A. Stahel, J. Bernhard et al. · Annals of Oncology · 2007 · 318 citations · Full text

Medicine, Oncology, Surgery +13